Loading...
Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours.
Evans, T Dean, Emma J Molife, L Lopez, J Ranson, M El-Khouly, F Zubairi, I Savulsky, C Reyderman, L Jia, Y
Evans, T
Dean, Emma J
Molife, L
Lopez, J
Ranson, M
El-Khouly, F
Zubairi, I
Savulsky, C
Reyderman, L
Jia, Y
Citations
Altmetric:
Abstract
BACKGROUND:
This phase 1 study examined the safety, tolerability, pharmacokinetics and preliminary efficacy of eribulin-liposomal formulation (eribulin-LF) in patients with advanced solid tumours.
METHODS:
Eligible patients with ECOG PS 0-1 were treated with eribulin-LF either on day 1 every 21 days (Schedule 1), or on days 1 and 15 every 28 days (Schedule 2). Doses ranged from 1.0 to 3.5?mg/m2, with dose escalation in a 3?+?3 design. The dose-expansion phase evaluated eribulin-LF in select tumour types.
PRIMARY OBJECTIVES:
maximum tolerated dose (MTD) and the recommended dose/schedule of eribulin-LF.
RESULTS:
Totally, 58 patients were enroled (median age?=?62 years). The MTD was 1.4?mg/m2 (Schedule 1) or 1.5?mg/m2 (Schedule 2), the latter dose selected for the dose-expansion phase. Dose-limiting toxicity (DLTs) in Schedule 1: hypophosphatemia and increased transaminase levels. DLTs in Schedule 2: stomatitis, increased alanine aminotransferase, neutropenia and febrile neutropenia. The pharmacokinetic profile of eribulin-LF showed a similar half-life to that of eribulin (~30?h), but with a 5-fold greater maximum serum concentration and a 40-fold greater area-under-the-curve. Eribulin-LF demonstrated clinical activity with approximately 10% of patients in both schedules achieving partial responses.
CONCLUSIONS:
Eribulin-LF was well tolerated with a favourable pharmacokinetic profile. Preliminary evidence of clinical activity in solid tumours was observed.
Description
Date
2019
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 609.67 KB
Keywords
Type
Article
Citation
Evans TRJ, Dean E, Molife LR, Lopez J, Ranson M, El-Khouly F, et al. Phase 1 dose-finding and pharmacokinetic study of eribulin-liposomal formulation in patients with solid tumours. Br J Cancer. 2019 Jan 25.